A phase II open-label single arm trial of nivolumab ipilimumab and short-course radiotherapy in adults with newly diagnosed MGMT unmethylated glioblastoma

Brief description of study

If you have been diagnosed with a form of brain cancer called glioblastoma and you have not received any therapy for your tumor other than surgery, you may be qualified to participate in a study evaluating a short course of radiation therapy, a drug called nivolumab, and a drug called ipilimumab. The goal of this phase II study is to test whether the combination of these drugs causes any side effects.

Clinical Study Identifier: s17-00218
ClinicalTrials.gov Identifier: NCT03367715
Principal Investigator: Sylvia C. Kurz
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.